A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1 | Zendy

David B. Huang | Zendy; William O’Riordan | Zendy; J. Scott Overcash | Zendy; Barry Heller | Zendy; Faisal Amin | Zendy; Thomas M. File | Zendy; Mark H. Wilcox | Zendy; Antoni Torres | Zendy; Matthew Dryden | Zendy; Thomas L Holland | Zendy; Patrick McLeroth | Zendy; Rajesh Shukla | Zendy; G. Ralph Corey | Zendy

Open Access

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1

Author(s) -

David B. Huang,

William O’Riordan,

J. Scott Overcash,

Barry Heller,

Faisal Amin,

Thomas M. File,

Mark H. Wilcox,

Antoni Torres,

Matthew Dryden,

Thomas L Holland,

Patrick McLeroth,

Rajesh Shukla,

G. Ralph Corey

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix987

Subject(s) - medicine , vancomycin , clinical endpoint , adverse effect , methicillin resistant staphylococcus aureus , randomized controlled trial , surgery , antibacterial agent , phases of clinical research , clinical trial , antibiotics , staphylococcus aureus , microbiology and biotechnology , biology , bacteria , genetics

Our objective in this study was to demonstrate the safety and efficacy of iclaprim compared with vancomycin for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSIs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research